Kouki Harasaki is the Founding / Managing Partner at Bioluminescence Ventures.

Dr. Harasaki has over 25 years of biomedical science experience working across major health systems, research institutes, biopharmaceutical corporations, technology companies, and venture capital firms. He has led over $600M in financing deals that have funded over 25 therapeutics programs across stages (discovery to marketed), across therapeutic areas (Cardiovascular & Metabolism, Immunology, Oncology, Neuro/CNS), and across modalities (small molecules, biologics, genome editing platforms, cell therapies).

Prior to founding Bioluminescence Ventures, he was a Managing Director at M12 / Microsoft Ventures, where he led Life Science investments and helped develop Microsoft Life Science corporate strategy. Prior to M12, Dr. Harasaki was a senior Partner at Andreessen Horowitz, where he managed four Bio Fund Partners and worked across the portfolio of 25+ Bio Fund companies.

Prior to his time in venture, Dr. Harasaki held Drug Discovery, Animal Pharmacology, Corporate Strategy, Finance, and Business Development roles at Novartis AG, Baxalta/Shire, and Genentech/Roche. At Novartis AG, he was a member of the M&A deal team that ultimately generated the $20B GSK – Novartis AG asset swap transaction of 2015 – involving Novartis Vaccines, Novartis Diagnostics, Novartis Consumer Health, and GSK Oncology business units. At Baxalta, he was responsible for developing the company’s Oncology/IO corporate strategy, executing that strategy by leading multiple $1B+ transactions, and building the foundational pipeline and portfolio for its new Oncology business unit. After the $32B acquisition of Baxalta by Shire in 2016, these Oncology marketed products and now clinical-stage pipeline assets continue to live on across multiple corporations to this day.

Prior to Bioluminescence Ventures, Angela worked in the Global Investment Banking group at Goldman Sachs covering Biopharma, MedTech, and Tools/Diagnostics clients. Prior to Goldman Sachs, she worked in the Equity Research division at Evercore covering SMID Cap Biotechs on the Biopharma team. Prior to her time in biopharma investment banking and equity research, Angela worked in the Chemistry Research division of Moderna, where she synthesized lipid nanoparticles for their proprietary delivery system. Prior Moderna, she researched molecules and mechanisms affecting synapse formation in the Umemori Lab at Harvard Medical School. Angela has served as a venture partner for Fourth Realm, a tech-focused VC fund investing across the lifecycle from Seed to Pre-IPO. She was also a venture partner for Ennovate Ventures, a micro-fund investing in early-stage African startups. Angela co-founded and serves as Chief Operating Officer of Plumar, an EdTech / Human-Resources start-up working to bridge US Tech companies with talent in underserved communities.

Dr. Kim is a PhD biomedical engineer by training, with scientific expertise in Regenerative Medicine, Oncology, Immunology, and Neuro/CNS. Prior to joining Bioluminescence Ventures, she was a business development lead at Yuhan – a multi-billion dollar market cap biopharmaceutical corporation developing therapeutics in Oncology, Metabolism, and Neuro/CNS therapeutic areas. Prior to that, Dr. Kim was a consultant at Charles River Associates, where she focused on Oncology and Immunology engagements.

Dr. Jin is a PhD molecular biologist and MBA by training, with expertise in gene therapy, synthetic biology, biomaterials, and microbiome. Prior to Bioluminescence Ventures, he was a Senior Vice President at Hanwha Group, a major Fortune Global 500 corporation. There, he led Corporate Strategy, Equity Investments, and Research for their emerging biotechnology business. Prior to that, Dr. Jin was the President of CJ Biomaterials (formerly Metabolix) division of CJ Group, a $1B+ diversified corporation. There, he oversaw R&D and equity investments across biotherapeutics and synthetic biology.

Minish is an MBA by training, with expertise in biopharmaceutical research strategy, portfolio strategy, manufacturing, pricing, and analytics. Prior to Bioluminescence Ventures, he has 10 years of biopharmaceutical consulting and market research experience at Boston Consulting Group and Evalueserve – where he focused on Oncology, Cardiology, Neuro/CNS, Immunology, and Genetic Disease engagements.